Research progress of exosomes in lung cancer
达格列净对冠心病合并心力衰竭患者的应用临床效果探讨

摘要

目的 本文将深入探讨针对冠心病合并心力衰竭患者，应用达格列净治疗的临床效果，从而改善患者临床症状，提升生活质量。方法 抽取我院2021年1月-2022年6月期间，共68例冠心病合并心力衰竭患者，患者知情参与至常规组（34人）与治疗组（34人），常规组给予常规治疗，治疗组在此基础上配合达格列净药物治疗，比较两组患者临床治疗效果情况。结果 治疗前所有患者心功能水平并无较大差异，（p＞0.05），治疗后，治疗组患者各项心功能指标均优于常规组，（P＜0.05）；治疗前患者炎性指标无较大差异，（P＞0.05），治疗后治疗组炎性指标改善效果更优于常规组，（P＜0.05）；两组患者治疗效果存在差异较大，（P＜0.05），其改善率对比为治疗组：常规组94.12%：73.53%；治疗组治疗满意度（97.06%）远优于常规组（76.47%，（P＜0.05）。结论 临床治疗冠心病合并心力衰竭患者，常规治疗基础上应用达格列净药物，临床治疗效果理想，可有效改善临床症状，提升心功能，降低炎性指标，患者治疗满意度较高，利于提升临床治疗效果及服务质量。

Abstract

Objective This article will delve into the clinical effects of applying dapagliptin to patients with coronary heart disease and heart failure, in order to improve their clinical symptoms and quality of life.
Methods A total of 68 patients with coronary heart disease and heart failure were selected from our hospital from January 2021 to June 2022. The patients were informed to participate in the conventional group (34 people) and the treatment group (34 people). The conventional group was given routine treatment, and the treatment group was treated with dapagliptin on this basis. The clinical treatment effect of the two groups of patients was compared.
Results There was no significant difference in cardiac function levels among all patients before treatment (p>0.05). After treatment, all cardiac function indicators in the treatment group were better than those in the conventional group (P<0.05); There was no significant difference in inflammatory indicators among patients before treatment (P>0.05), and the improvement effect of inflammatory indicators in the treatment group was better than that in the conventional group after treatment (P<0.05); There is a significant difference in the treatment effect between the two groups of patients (P<0.05), and the improvement rate is compared to the treatment group: 94.12% in the conventional group: 73.53%; The treatment group's treatment satisfaction (97.06%) was much better than the conventional group's (76.47%, P<0.05).
Conclusion   In clinical treatment of patients with coronary heart disease combined with heart failure, the use of daggliflozin on the basis of conventional treatment has ideal clinical treatment effects, which can effectively improve clinical symptoms, enhance heart function, and reduce inflammatory indicators. Patients have high satisfaction with treatment, which is conducive to improving clinical treatment effectiveness and service quality.